

ACORDA THERAPEUTICS INC  
Form SC 13D/A  
May 28, 2009

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**SCHEDULE 13D  
Under the Securities Exchange Act of 1934**

**(Final Amendment)**

**Acorda Therapeutics, Inc.**

(Name of Issuer)

**Common Stock, par value \$0.001 per share**

(Title of Class of Securities)

**00484M106**

(CUSIP Number)

**Simon M. Lorne, Esq.  
Millennium Management LLC  
666 Fifth Avenue, 8th Floor  
New York, New York 10103  
(212) 841-4100**

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

**May 26, 2009**

(Date of event which requires filing of this statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of § 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g) check the following box .

---

**SCHEDULE 13D**

<b>CUSIP No.</b> 00484M106	
<b>1</b>	NAMES OF REPORTING PERSONS Millenco LLC
<b>2</b>	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) <input type="radio"/> (b) <input type="radio"/>
<b>3</b>	SEC USE ONLY
<b>4</b>	SOURCE OF FUNDS WC, OO
<b>5</b>	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)  <input type="radio"/>
<b>6</b>	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	<b>7</b> SOLE VOTING POWER -0-
	<b>8</b> SHARED VOTING POWER 1,240,777 (See Items 5 and 6)
	<b>9</b> SOLE DISPOSITIVE POWER -0-
	<b>10</b> SHARED DISPOSITIVE POWER 1,240,777 (See Items 5 and 6)
<b>11</b>	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,240,777 (See Items 5 and 6)
<b>12</b>	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES <input type="radio"/>
<b>13</b>	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 3.3%
<b>14</b>	TYPE OF REPORTING PERSON OO, BD

**SCHEDULE 13D**

<b>CUSIP No.</b> 00484M106	
<b>1</b>	NAMES OF REPORTING PERSONS Integrated Core Strategies (US) LLC
<b>2</b>	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) <input type="radio"/> (b) <input type="radio"/>
<b>3</b>	SEC USE ONLY
<b>4</b>	SOURCE OF FUNDS WC, OO
<b>5</b>	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) <input type="radio"/>
<b>6</b>	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	<b>7</b> SOLE VOTING POWER -0-
	<b>8</b> SHARED VOTING POWER 290,100 (See Items 5 and 6)
	<b>9</b> SOLE DISPOSITIVE POWER -0-
	<b>10</b> SHARED DISPOSITIVE POWER 290,100 (See Items 5 and 6)
<b>11</b>	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 290,100 (See Items 5 and 6)
<b>12</b>	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES <input type="radio"/>
<b>13</b>	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 0.8%
<b>14</b>	TYPE OF REPORTING PERSON OO

**SCHEDULE 13D**

<b>CUSIP No.</b> 00484M106	
<b>1</b>	NAMES OF REPORTING PERSONS Catapult Partners, Ltd.
<b>2</b>	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) <input type="radio"/> (b) <input type="radio"/>
<b>3</b>	SEC USE ONLY
<b>4</b>	SOURCE OF FUNDS WC, OO
<b>5</b>	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) <input type="radio"/>
<b>6</b>	CITIZENSHIP OR PLACE OF ORGANIZATION Cayman Islands
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	<b>7</b> SOLE VOTING POWER -0-
	<b>8</b> SHARED VOTING POWER -0- (See Introduction)
	<b>9</b> SOLE DISPOSITIVE POWER -0-
	<b>10</b> SHARED DISPOSITIVE POWER -0- (See Introduction)
<b>11</b>	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON -0- (See Introduction)
<b>12</b>	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES <input type="radio"/>
<b>13</b>	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 0.0%
<b>14</b>	TYPE OF REPORTING PERSON CO

**SCHEDULE 13D**

<b>CUSIP No.</b> 00484M106	
<b>1</b>	NAMES OF REPORTING PERSONS Catapult Capital Management LLC
<b>2</b>	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) <input type="radio"/> (b) <input type="radio"/>
<b>3</b>	SEC USE ONLY
<b>4</b>	SOURCE OF FUNDS WC, OO
<b>5</b>	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) <input type="radio"/>
<b>6</b>	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	<b>7</b> SOLE VOTING POWER -0-
	<b>8</b> SHARED VOTING POWER -0- (See Introduction)
	<b>9</b> SOLE DISPOSITIVE POWER -0-
	<b>10</b> SHARED DISPOSITIVE POWER -0- (See Introduction)
<b>11</b>	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON -0- (See Introduction)
<b>12</b>	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES <input type="radio"/>
<b>13</b>	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 0.0%
<b>14</b>	TYPE OF REPORTING PERSON OO

**SCHEDULE 13D**

<b>CUSIP No.</b> 00484M106	
<b>1</b>	NAMES OF REPORTING PERSONS Millennium International Management LP
<b>2</b>	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) <input type="radio"/> (b) <input type="radio"/>
<b>3</b>	SEC USE ONLY
<b>4</b>	SOURCE OF FUNDS WC, OO
<b>5</b>	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) <input type="radio"/>
<b>6</b>	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	<b>7</b> SOLE VOTING POWER -0-
	<b>8</b> SHARED VOTING POWER -0- (See Introduction)
	<b>9</b> SOLE DISPOSITIVE POWER -0-
	<b>10</b> SHARED DISPOSITIVE POWER -0- (See Introduction)
<b>11</b>	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON -0- (See Introduction)
<b>12</b>	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES <input type="radio"/>
<b>13</b>	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 0.0%
<b>14</b>	TYPE OF REPORTING PERSON HC, PN

**SCHEDULE 13D**

<b>CUSIP No.</b> 00484M106	
<b>1</b>	NAMES OF REPORTING PERSONS Millennium International Management GP LLC
<b>2</b>	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) <input type="radio"/> (b) <input type="radio"/>
<b>3</b>	SEC USE ONLY
<b>4</b>	SOURCE OF FUNDS WC, OO
<b>5</b>	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) <input type="radio"/>
<b>6</b>	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	<b>7</b> SOLE VOTING POWER -0-
	<b>8</b> SHARED VOTING POWER -0- (See Introduction)
	<b>9</b> SOLE DISPOSITIVE POWER -0-
	<b>10</b> SHARED DISPOSITIVE POWER -0- (See Introduction)
<b>11</b>	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON -0- (See Introduction)
<b>12</b>	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES <input type="radio"/>
<b>13</b>	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 0.0%
<b>14</b>	TYPE OF REPORTING PERSON OO

**SCHEDULE 13D**

<b>CUSIP No.</b> 00484M106	
<b>1</b>	NAMES OF REPORTING PERSONS Millennium Management LLC
<b>2</b>	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) <input type="radio"/> (b) <input type="checkbox"/>
<b>3</b>	SEC USE ONLY
<b>4</b>	SOURCE OF FUNDS WC, OO
<b>5</b>	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) <input type="checkbox"/>
<b>6</b>	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	<b>7</b> SOLE VOTING POWER -0-
	<b>8</b> SHARED VOTING POWER 1,530,877 (See Items 5 and 6)
	<b>9</b> SOLE DISPOSITIVE POWER -0-
	<b>10</b> SHARED DISPOSITIVE POWER 1,530,877 (See Items 5 and 6)
<b>11</b>	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,530,877 (See Items 5 and 6)
<b>12</b>	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES <input type="radio"/>
<b>13</b>	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 4.0%
<b>14</b>	TYPE OF REPORTING PERSON OO



## SCHEDULE 13D

<b>CUSIP No.</b> 00484M106		
<b>1</b>	NAMES OF REPORTING PERSONS Israel A. Englander	
<b>2</b>	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) <input type="radio"/> (b) <input type="checkbox"/>	
<b>3</b>	SEC USE ONLY	
<b>4</b>	SOURCE OF FUNDS  WC, OO	
<b>5</b>	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) <input type="checkbox"/>	
<b>6</b>	CITIZENSHIP OR PLACE OF ORGANIZATION United States	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	<b>7</b>	SOLE VOTING POWER -0-
	<b>8</b>	SHARED VOTING POWER 1,530,877 (See Items 5 and 6)
	<b>9</b>	SOLE DISPOSITIVE POWER -0-
	<b>10</b>	SHARED DISPOSITIVE POWER 1,530,877 (See Items 5 and 6)
<b>11</b>	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,530,877 (See Items 5 and 6)	
<b>12</b>	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES <input type="radio"/>	
<b>13</b>	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 4.0%	
<b>14</b>	TYPE OF REPORTING PERSON IN	

## Explanatory Note

### Introduction

This Final Amendment to Schedule 13D ("Final Amendment to Schedule 13D"), amends and restates the Schedule 13D ("Schedule 13D"), filed on April 13, 2009 by the Reporting Persons (as defined in Item 2, below), relating to their beneficial ownership of the common stock, par value \$0.001 per share (the "Common Stock"), of Acorda Therapeutics, Inc., a Delaware corporation (the "Issuer").

This Final Amendment to Schedule 13D reflects a material change in the number of shares beneficially owned or deemed to be beneficially owned by Millenco LLC, Millennium Management LLC and/or Israel A. Englander, as the case maybe, and the percentage of class represented by such ownership since the filing of the Schedule 13D. In addition, as of the date of this Final Amendment to Schedule 13D, Catapult Partners, Ltd. is no longer the beneficial owner of any shares of the Issuer's Common Stock. Consequently, Catapult Capital Management LLC, Millennium International Management LP, Millennium International Management GP LLC, Millennium Management LLC and Israel A. Englander are no longer deemed to be beneficial owners of any shares of the Issuer's Common Stock formerly owned by Catapult Partners, Ltd.

### Item 1. Security and Issuer.

The name of the Issuer is Acorda Therapeutics, Inc. The address of the Issuer's principal executive offices is 15 Skyline Drive, Hawthorne, New York 10532. This Final Amendment to Schedule 13D relates to the Issuer's Common Stock.

### Item 2. Identity and Background.

(a)-(c), (f). This statement is being filed by Millenco LLC, a Delaware limited liability company ("Millenco"), Integrated Core Strategies (US) LLC, a Delaware limited liability company ("Integrated Core Strategies"), and Catapult Partners, Ltd., an exempted limited company organized under the laws of the Cayman Islands ("Catapult Partners"). Millenco is a broker-dealer and a member of the American Stock Exchange and the NASDAQ.

Millennium Management LLC, a Delaware limited liability company ("Millennium Management"), is the manager of Millenco, and may be deemed to have shared voting control and investment discretion over securities owned by Millenco. Millennium Management is also the general partner of the managing member of Integrated Core Strategies and may be deemed to have shared voting control and investment discretion over securities owned by Integrated Core Strategies.

Israel A. Englander, a United States citizen ("Mr. Englander"), is the managing member of Millennium Management. Consequently, Mr. Englander may also be deemed to be the beneficial owner of any securities owned by Millenco and Integrated Core Strategies.

The foregoing should not be construed in and of itself as an admission by Millennium Management or Mr. Englander as to the shares of the Issuer's Common Stock beneficially owned by Millenco and/or Integrated Core Strategies, as the case may be.

Millenco, Integrated Core Strategies, Catapult Partners, Catapult Capital Management LLC, Millennium International Management LP and Millennium International Management GP LLC, Millennium Management and Mr. Englander will be collectively referred to as the reporting persons ("Reporting Persons") in this Final Amendment to Schedule 13D.

The business address for Millenco, Integrated Core Strategies and Mr. Englander is c/o Millennium Management LLC, 666 Fifth Avenue, New York, New York 10103. The business address for Catapult Partners, Catapult Capital Management LLC and Millennium International Management LP is c/o Millennium International Management GP, 666 Fifth Avenue, New York, New York 10103. The business address for Millennium Management and Millennium International Management GP LLC is 666 Fifth Avenue, New York, New York 10103.

(d) During the last five years, none of the Reporting Persons has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

(e) On December 1, 2005, Millennium Management and Mr. Englander, together with Millennium Partners, L.P. ("Millennium Partners") and certain related persons and entities, entered into settlements with the Securities and Exchange Commission ("SEC") and the Attorney General of the State of New York (the "NYAG") relating to allegations that Millennium Partners had engaged in a pattern of deceptive "market timing" of mutual fund shares in years prior to 2004 and, in the case of the settlement with the NYAG only, had failed to take adequate steps to prevent a trader from engaging in mutual fund "late trading" in violation of firm policy. The parties neither admitted nor denied the allegations or findings (except as to jurisdiction) but consented to the entry of findings. The SEC proceedings are In the Matter of Millennium Partners, L.P., et al. Securities Act Release No. 8639 (December 1, 2005), available at [www.sec.gov](http://www.sec.gov). Contemporaneously, the NYAG issued an Assurance of Discontinuance relating to the claims and findings of that office.

Neither the Reporting Persons nor any other party admitted or denied any of the allegations or findings in these matters. The remedies included disgorgement by the entities of approximately \$148 million of mutual fund trading profits, civil penalties aggregating approximately \$32.15 million (with approximately \$30 million being paid by Mr. Englander), an administrative order to cease and desist from violations of the antifraud provisions of the Securities Act of 1933 and the Securities Exchange Act of 1934 (the "Exchange Act"), and prophylactic relief.

### **Item 3. Source and Amount of Funds or Other Consideration.**

The amount of funds used to purchase the 1,240,777 and 290,100 shares of the Issuer's Common Stock held by Millenco and Integrated Core Strategies was approximately, \$28,479,104 and \$6,877,528, respectively, calculated on an average cost basis (excluding brokerage commissions) by account. Millenco and Integrated Core Strategies effect purchases of securities primarily through margin accounts maintained for them with prime brokers, which may extend margin credit to Millenco and Integrated Core Strategies as and when required to open or carry positions in the margin accounts, subject to applicable margin regulations, stock exchange rules and the prime broker's credit policies. In such instances, the positions held in the margin accounts are pledged as collateral security for the repayment of debit balances in the accounts.

### **Item 4. Purpose of Transaction.**

The Reporting Persons are engaged in the investment business. In pursuing this business, the Reporting Persons analyze the operations, capital structure and markets of companies, including the Issuer, on a continuous basis, through analysis of documentation and discussions with knowledgeable industry and market observers and with representatives of such companies (often at the invitation of management). From time to time, one or more of the Reporting Persons may hold discussions with third parties or with management of such companies in which the Reporting Persons may suggest or take a position with respect to potential changes in the operations, management or capital structure of such companies as a means of enhancing shareholder value. Such suggestions or positions may relate to one or more of the transactions specified in clauses (a) through (j) of Item 4 of Schedule 13D of the Exchange Act, including, without limitation, such matters as disposing of or selling all or a portion of the company or acquiring another company or business, changing operating or marketing strategies, adopting or not adopting certain types of anti-takeover measures and restructuring the Issuer's capitalization or dividend policy.

The Reporting Persons employ the services of a number of portfolio managers, each of whom independently employs a separate and distinct trading strategy. A portion of the securities of the Issuer held by the Reporting Persons are held in accounts of the Reporting Persons managed by portfolio managers who engage in event-, risk- or merger-arbitrage or fundamental strategies.

Except as set forth above, the Reporting Persons do not have any present plans or proposals that relate to or would result in any of the actions required to be described in Item 4 of this Final Amendment to Schedule 13D. Each of the Reporting Persons may, at any time, review or reconsider its position with respect to the Issuer and formulate plans or proposals with respect to any of such matters, but has no present intention of doing so.

**Item 5. Interest in Securities of the Issuer.**

(a) As of the date this filing, Millenco is the beneficial owner of 1,240,777 shares of the Issuer's Common Stock and Integrated Core Strategies is the beneficial owner of 290,100 shares of the Issuer's Common Stock.

Millennium Management, as the manager of Millenco, may be deemed to beneficially own the above-described shares of the Issuer's Common Stock beneficially owned by Millenco. Millennium Management, as the general partner of the managing member of Integrated Core Strategies, may also be deemed to beneficially own the above-described shares of the Issuer's Common Stock beneficially owned by Integrated Core Strategies.

Mr. Englander, as the managing member of Millennium Management, may also be deemed to beneficially own the above-described shares of the Issuer's Common Stock beneficially owned by Millenco and Integrated Core Strategies.

Accordingly, as of the date of this filing, Mr. Englander and Millennium Management may be deemed to be beneficial owners of 1,530,877 shares or 4.0% of the Issuer's Common Stock. The calculation of the foregoing percentage is on the basis of 38,011,594 shares of the Issuer's Common Stock outstanding as of April 30, 2009, as per the Issuer's Form 10-Q, dated May 11, 2009. The foregoing should not be construed in and of itself as an admission by Millennium Management or Mr. Englander as to beneficial ownership of the shares held by Millenco, and/or Integrated Core Strategies, as the case may be.

(b) Millenco may be deemed to hold shared power to vote and to dispose of the 1,240,777 shares of the Issuer's Common Stock described in (a) above. Integrated Core Strategies may be deemed to hold shared power to vote and dispose of the 290,100 shares of the Issuer's Common Stock described in (a) above. Mr. Englander and Millennium Management may be deemed to hold shared power to vote and to dispose of the 1,530,877 shares of the Issuer's Common Stock. The foregoing should not be construed in and of itself as an admission by Millennium Management or Mr. Englander as to the shares of the Issuer's Common Stock beneficially owned by Millenco and/or Integrated Core Strategies, as the case may be.

(c) Transactions in the Issuer's Common Stock since and including April 13, 2009, the date that the Schedule 13D was filed with the SEC: Schedule A annexed hereto lists all transactions in the Issuer's Common Stock by the Reporting Persons since and including April 13, 2009, the date that the Schedule 13D was filed with the SEC. All of the transactions in the Issuer's Common Stock were effected by either Millenco, Integrated Core Strategies, Catapult Partners or Cognizant Holdings, Ltd., (an affiliate of the Reporting Persons), in the open market.

(d) No person other than the Reporting Persons is known to have the right to receive, or the power to direct the receipt of, dividends from, or proceeds from the sale of, the shares of Common Stock reported in this Final Amendment to Schedule 13D.

(e) On May 18, 2009, the Reporting Persons ceased to beneficially own in excess of 5% of the Issuer's Common Stock. However, the Reporting Persons deem May 26, 2009 to be the relevant date of event for this Final Amendment to Schedule 13D, as it is the date on which a material change in the number of shares beneficially owned or deemed to

be beneficially owned and the percentage of class represented by such ownership since the filing of the Schedule 13D occurred.

**Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.**

Millenco has an open short position of 91,824 shares of the Issuer's Common Stock, which position is not netted against the data provided herein for the purposes of determining the number of shares beneficially owned by any of the Reporting Persons.

Cognizant Holdings, Ltd., an affiliate of the Reporting Persons, has an open short position of 11,746 shares of the Issuer's Common Stock, which position is not netted against the data provided herein for the purposes of determining the number of shares beneficially owned by any of the Reporting Persons.

In connection with arrangements with Millenco's and Integrated Core Strategies' prime brokers, such prime brokers are permitted to lend securities in Millenco's and Integrated Core Strategies' accounts to the extent permitted by debit balances in such accounts. Millenco and Integrated Core Strategies generally will not have any knowledge of the specific loans made by such prime brokers. In addition, in the ordinary course of business, Millenco and Integrated Core Strategies (or their prime brokers), may borrow securities to satisfy delivery obligations arising from short sales. In addition, Millenco may lend securities to third parties and such loans generally may be recalled upon demand, but may not be able to be recalled in advance of an applicable record date and thus, such loaned shares may not be able to be voted by Millenco. Similarly, it should also be noted that shares lent by Millenco's and Integrated Core Strategies', prime brokers may not be able to be recalled in advance of an applicable record date and thus, such loaned shares may not be able to be voted by Millenco or Integrated Core Strategies.

There are no other contracts, arrangements, understandings or relationships among the Reporting Persons, or between the Reporting Persons and any other person, with respect to the securities of the Issuer.

**Item 7. Material to Be Filed as Exhibits.**

Exhibit I: Joint Filing Agreement, dated as of May 27, 2009, by and among Millenco LLC, Integrated Core Strategies (US) LLC, Catapult Partners, Ltd., Catapult Capital Management LLC, Millennium International Management LP, Millennium International Management GP LLC, Millennium Management LLC and Israel A. Englander.

---

Edgar Filing: ACORDA THERAPEUTICS INC - Form SC 13D/A

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: May 27, 2009

MILLENCO LLC

By: /s/Mark Meskin  
Name: Mark Meskin  
Title: Chief Executive Officer

INTEGRATED CORE STRATEGIES (US) LLC

By: Integrated Holding Group LP,  
its managing member

By: Millennium Management LLC,  
its general partner

By: /s/ David Nolan  
Name: David Nolan  
Title: Co-President

CATAPULT PARTNERS, LTD.

By: Catapult Capital Management LLC,  
its investment manager

By: Millennium International Management LP,  
its managing member

By: /s/ David Nolan  
Name: David Nolan  
Title: Co-President

CATAPULT CAPITAL MANAGEMENT LLC

By: Millennium International Management LP,  
its managing member

By: /s/ David Nolan  
Name: David Nolan  
Title: Co-President

MILLENNIUM INTERNATIONAL MANAGEMENT LP

By: /s/David Nolan

Edgar Filing: ACORDA THERAPEUTICS INC - Form SC 13D/A

Name: David Nolan  
Title: Co-President

MILLENNIUM INTERNATIONAL MANAGEMENT GP LLC

By: /s/David Nolan  
Name: David Nolan  
Title: Executive Vice President

MILLENNIUM MANAGEMENT LLC

By: /s/David Nolan  
Name: David Nolan  
Title: Co-President

/s/ Israel A. Englander by David Nolan  
pursuant to Power of Attorney filed with  
the SEC on June 6, 2005  
Israel A. Englander

---

Edgar Filing: ACORDA THERAPEUTICS INC - Form SC 13D/A

EXHIBIT I

JOINT FILING AGREEMENT

This will confirm the agreement by and among the undersigned that the Schedule 13D filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership of the Common Stock, par value \$0.001 per share, of Acorda Therapeutics, Inc., a Delaware corporation, is being filed and all amendments thereto will be filed, on behalf of each of the persons and entities named below in accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

Dated: May 27, 2009

MILLENCO LLC

By: /s/Mark Meskin  
Name: Mark Meskin  
Title: Chief Executive Officer

INTEGRATED CORE STRATEGIES (US) LLC

By: Integrated Holding Group LP,  
its managing member

By: Millennium Management LLC,  
its general partner

By: /s/ David Nolan  
Name: David Nolan  
Title: Co-President

CATAPULT PARTNERS, LTD.

By: Catapult Capital Management LLC,  
its investment manager

By: Millennium International Management LP,  
its managing member

By: /s/ David Nolan  
Name: David Nolan  
Title: Co-President

CATAPULT CAPITAL MANAGEMENT LLC

By: Millennium International Management LP,  
its managing member